Tough Times In Europe For Gene Therapy Companies
Zynteglo Failure Will Be Worrying For Fellow Gene Therapy Developers
bluebird bio's decision to wind down commercial initiatives for its gene therapy business in Europe is a blow for the sector in the region as a whole.
You may also be interested in...
A bluebird executive spoke during ARM’s Cell and Gene Meeting On The Mesa about why the firm pulled Zynteglo out of the EU, but while progress has been made in the US, long-term challenges remain.
Bluebird bio’s decision to focus on the US market is being seen as a broader signal of the need for changes in market access policies to enable gene therapies to be made available for European patients. Only collaborative work will create solutions acceptable to payers and companies, and finding an acceptable price that both can live with will be crucial.
The Netherlands calls for multi-country price negotiations for gene therapy Zynteglo.